GMP Non-Compliance

Information is now publicly available via the EudraGMDP data base.

The European Medicines Agency (EMA) has launched a new version of the EudraGMDP database which includes, among other changes, the publication of statements of non-compliance with Good Manufacturing Practice. Statements of non-compliance contain information on the nature of the non-compliance and the actions taken or proposed by the issuing authority in order to protect public health.

These statements aim to establish a coordinated and harmonized response by the network of European Union (EU) medicines regulators. Some non-compliance statements are the result of inspections carried out by the EDQM with the participation of EU/EEA national inspectorates. Any statement of GMP non-compliance that is related to a manufacturing site covered by a CEP application initiates the decision making process on the validity of the CEPs concerned by the EDQM, regardless of whether the EDQM has been involved in the inspection or not.

Information of a commercially or personally confidential nature is not made public. The decision on which information to make public is taken by the medicines regulatory authority in the EU Member State that adds the information to the database.

• Read the current Non-Compliance Reports

Read the updates on the last six months:

• CEP suspensions
• CEP withdrawals
• CEP restoration

CEP Suspensions

1.Upon request from the holder, due to a temporary inability to produce under the approved conditions

2. Due to GMP non-compliance

3. Due to a failure to fulfil the requirements of the Certification procedure

Return to top

CEP Withdrawals

1. Due to GMP non-compliance

2. Due to a failure to fulfill the requirements of the Certification Procedure

3. Due to the deletion of the monograph from the European Pharmacopoeia

Restoration of suspended CEP

Return to top